Trade Report: The NewLink Genetics Corp. (NASDAQ:NLNK) Receives $25.40 Average Price Target from Analysts

The NewLink Genetics Corp. (NASDAQ:NLNK) Receives $25.40 Average Price Target from Analysts

Shares of NewLink Genetics Corp. (NASDAQ:NLNK) have received a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $25.40.

Separately, Zacks Investment Research upgraded shares of NewLink Genetics Corp. from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Tuesday, July 5th.

NewLink Genetics Corp. (NASDAQ:NLNK) opened at 15.30 on Thursday. The firm’s market capitalization is $443.23 million. NewLink Genetics Corp. has a 12 month low of $9.23 and a 12 month high of $46.34. The company’s 50 day moving average price is $11.71 and its 200 day moving average price is $12.76.

NewLink Genetics Corp. (NASDAQ:NLNK) last released its quarterly earnings data on Friday, July 29th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.77) by $0.35. NewLink Genetics Corp. had a negative return on equity of 51.33% and a negative net margin of 316.38%. Analysts anticipate that NewLink Genetics Corp. will post ($3.06) EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors boosted its position in NewLink Genetics Corp. by 5.8% in the second quarter. Nationwide Fund Advisors now owns 14,160 shares of the company’s stock valued at $159,000 after buying an additional 770 shares during the period. State Board of Administration of Florida Retirement System boosted its position in NewLink Genetics Corp. by 5.8% in the second quarter. State Board of Administration of Florida Retirement System now owns 21,334 shares of the company’s stock valued at $240,000 after buying an additional 1,164 shares during the period. Quantitative Investment Management LLC boosted its position in NewLink Genetics Corp. by 188.4% in the second quarter. Quantitative Investment Management LLC now owns 62,000 shares of the company’s stock valued at $698,000 after buying an additional 40,500 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in NewLink Genetics Corp. by 3.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 163,131 shares of the company’s stock valued at $1,837,000 after buying an additional 4,959 shares during the period. Finally, California State Teachers Retirement System boosted its position in NewLink Genetics Corp. by 3.0% in the second quarter. California State Teachers Retirement System now owns 45,368 shares of the company’s stock valued at $511,000 after buying an additional 1,325 shares during the period. Institutional investors and hedge funds own 50.10% of the company’s stock.

Related posts

Leave a Comment